Altera™ Comprehensive Genomic Profiling
Use
Altera™ Comprehensive Genomic Profiling uses a combination of whole-exome and whole-transcriptome sequencing to deliver deep insights into a cancer’s unique genomic signature. It identifies clinically relevant biomarkers to assist in guiding patient management, including the selection of targeted therapies and immunotherapies, and identifying trial eligibility. This comprehensive report provides information on both common and rare but actionable biomarkers, supporting clinicians in making informed treatment decisions.
Special Instructions
Altera™ is designed to maximize patient insights using a single tumor sample. It enables streamlined ordering through a physician portal and fosters simpler logistics for patients. The test can be ordered alongside Signatera™ for comprehensive results.
Limitations
The test identifies genomic alterations such as SNVs, indels, CNAs, select gene rearrangements, MSI, and TMB, but may miss some novel drivers outside its panel scope. Some emerging biomarkers, though detected, might lack the clinical validation needed for widespread use. Identified markers' significance in trial matching may vary depending on the trial’s inclusion criteria.
Methodology
NGS (CGP)
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Tumor Tissue
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
Utilize a single tumor sample for testing. Ensure proper sample collection to conserve tissue and facilitate comprehensive profiling.